Navigation Links
Scios Announces Results From Exploratory Nesiritide Study Providing,Important New Renal and Mortality Safety Data with a Neutral Effect,on the Primary Endpoint

-- Data from Serial Outpatient Infusion Study in Patients with Chronic Decompensated Heart Failure Presented at the American College of Cardiology 56th Annual Scientific Session --

MOUNTAIN VIEW, Calif. and NEW ORLEANS, March 25, 2007 /PRNewswire/ -- Scios Inc. announced today that an exploratory, 920-patient, Phase 2 study of nesiritide (NATRECOR(R)) showed a neutral effect on the primary endpoint, a composite of death and cardiorenal hospitalization at 12 weeks, and provides important renal and mortality safety data on nesiritide in patients with advanced chronic decompensated heart failure (CDHF) receiving serial outpatient infusions.

Data from the study, known as FUSION II (Follow-Up Serial InfusiOns of NATRECOR(R) in Advanced Heart Failure), were presented during a late-breaking clinical trial session at the of Cardiology's 56th Annual Scientific Session in New Orleans (presentation #402-9). Scios also announced that it plans to submit the safety data from this and other recent trials to the U.S. Food and Drug Administration (FDA).

NATRECOR(R) is the only FDA-approved intravenous treatment for patients with acutely decompensated congestive heart failure (ADHF) who have dyspnea (shortness of breath) at rest or with minimal activity.

FUSION II was designed to assess the long-term safety and outcomes at six months of once- or twice-weekly infusions of nesiritide compared to placebo in persistently symptomatic CDHF patients. All patients received ongoing intensive heart failure disease management, including optimization of standard heart failure medications and once or twice weekly outpatient clinic visits. Patients who participated in this trial had to have two prior recent hospitalizations, either NYHA class III or IV heart failure and had to have been out of the hospital for at least five days prior to enrollment in the trial.

The study demonstrated comparable renal and mortality
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
(Date:1/23/2015)... Inc. (ICBU) has repositioned itself as a holding company with ... in the hydroponic, hemp and medical marijuana sectors. By acquiring ... sector, and recently partnering with the Chippewa Tribe Nation to ... iMD is committing to bring its vision to the market ...
(Date:1/23/2015)... 2015   Leatt Corporation  (OTCQB: LEAT), a global developer, ... forms of sports, including extreme motor sports, and whose ... that the UISP Lega Motociclismo Lombardia, an Italian motocross ... wear a neck brace during its racing competitions.  ...
(Date:1/23/2015)... , Jan. 23, 2015 Gem Pharmaceuticals announced today ... been enrolled into the Company,s Phase 2 clinical trial. ... of Gem,s lead compound, GPX-150 (an investigational medication), in ... metastatic disease. Logo - http://photos.prnewswire.com/prnh/20150123/170966LOGO ...
Breaking Medicine Technology:iMD Companies Poised to Make Impact in Multi-Billion Dollar Medical Marijuana Sector With Recent Investments and Strategic Partnerships 2Leatt Announces Neck Braces Now Required For Motocross/Minicross Racing In Italy 2Leatt Announces Neck Braces Now Required For Motocross/Minicross Racing In Italy 3Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2
... Medical Group,s (FMG) subsidiaries, VasoStar Inc., Mentor, Ohio  today ... Frontier grant to further develop and commercialize a novel ... Occlusions (CTOs), in lieu of invasive open heart surgery ... VasoStar,s primary clinical development partner is the Cleveland ...
... July 20, 2011 Advanced Health Media (AHM), the ... solutions for the pharmaceutical industry, has named James Burgess ... assumes responsibility from Jeff Brady who has served as ... as its President for 9 years. James brings over ...
Cached Medicine Technology:Frantz Medical Group Subsidiary, VasoStar, Awarded $1 Million Research Grant 2Frantz Medical Group Subsidiary, VasoStar, Awarded $1 Million Research Grant 3Advanced Health Media Announces New CEO 2
(Date:1/22/2015)... New York, NY (PRWEB) January 22, 2015 ... American College of Sports Medicine flagship journal Medicine ... supplementation with L-Citrulline before exercise may help reduce ... strenuous exercise. 1 , Participants in the ...
(Date:1/22/2015)... Recently, Weddingshe.com has added many trendy Champagne wedding ... revenues in the past three years. Today, the business announces ... According to the sales manager of the company, this is ... 2015. This point can be reflected on the discounted wedding ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Four years since the ... – which coincided with the marriage of Avasa & Matthew Love ... ROAD, which is scheduled for release through White Swan Records on ... that there is a sacred path available to all of us ...
(Date:1/22/2015)... 22, 2015 EBSCO Information Services ... expanding their relationship in an effort to further promote visibility ... While EBSCO has long made AMA journals available via its ... for The JAMA Network. , Long known as ...
(Date:1/22/2015)... January 22, 2015 JJsHouse.com is a famous ... Today, the business announces its latest collection of wedding ... “The most important issue is the wedding dress on your ... in a woman’s life. Every bride wants to find the ...
Breaking Medicine News(10 mins):Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:Weddingshe Announces A Special Offer On Its Popular Glamorous Wedding Dresses 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 4Health News:EBSCO Expands Partnership with the American Medical Association 2Health News:EBSCO Expands Partnership with the American Medical Association 3Health News:EBSCO Expands Partnership with the American Medical Association 4Health News:Find The Most Suitable Wedding Dress At JJsHouse.com 2
... ANA, Calif., Jan. 9 Grubb & Ellis,Healthcare REIT, ... two-property medical office building portfolio in San Antonio and,the ... acquisition closed in,December 2008. , ... Pecan Valley Medical,Office Building consists of approximately 60,000 square ...
... , NEW YORK, Jan. 9 A ... of juvenile myelomonocytic leukemia (JMML), a very rare form ... cord blood from the National Cord Blood Program (NCBP) of ... Blood Center.Juvenile myelomonocytic leukemia generally affects children under the age ...
... Study found impairments were mild, but they could signal ... Adults with diabetes now have to worry about whether ... report that declines in mental function are accelerated among ... analysis, published in the January issue of Neuropsychology ...
... The University of Texas Health Science Center at Houston ... in a ground-breaking area of genetic study known as ... to discover why some people with known risk factors ... may have to do with the interplay between their ...
... Jan. 9 Blue Shield of California has ... manage the company,s rapid growth and pursue new strategic initiatives. ... spearhead the company,s success, Blue Shield chairman and CEO Bruce ... , Paul Markovich, ...
... A study published today in The,Journal of Occupational and ... price tag for lupus - including medical,expenditures, absence from ... per patient. The mean cost climbed to more than ... disease nephritis, as it,often is. That,s more than the ...
Cached Medicine News:Health News:Grubb & Ellis Healthcare REIT Acquires Mountain Plains Portfolio in Texas 2Health News:Grubb & Ellis Healthcare REIT Acquires Mountain Plains Portfolio in Texas 3Health News:Grubb & Ellis Healthcare REIT Acquires Mountain Plains Portfolio in Texas 4Health News:Seventeen Months After Cord Blood Transplant - Child is Free of Signs of Cancer 2Health News:Diabetes Linked to Cognitive Problems 2Health News:UT leads $2.5 million training program in pioneering area of genetic research 2Health News:UT leads $2.5 million training program in pioneering area of genetic research 3Health News:Paul Markovich Named Chief Operating Officer of Blue Shield of California 2Health News:Paul Markovich Named Chief Operating Officer of Blue Shield of California 3Health News:Lupus is a Significant Cost to Employers, According to Thomson Reuters Study 2Health News:Lupus is a Significant Cost to Employers, According to Thomson Reuters Study 3